Pharma Equity Group A/S (PEG.CO)
Copenhagen · DKK · Healthcare · Biotechnology
DKK 0.0824 (+0.24%) as of
Key statistics
- Market cap
- 101.15M
- EPS (TTM)
- -0.0100
- Dividend yield
- 0.00%
- 52-week range
- 0.0602 – 0.1200
- Beta
- 1.06
- Profit margin
- 0.00%
- Volume
- 44.07k
About Pharma Equity Group A/S
Pharma Equity Group A/S, through its subsidiary, Reponex Pharmaceuticals A/S, a clinical-stage biopharmaceutical company, develops treatments for diseases that have patient and social impact for which the current therapy is lacking or in need of improvement. Its products under development, includes RNX-011 for the treatment of bacterial peritonitis; RNX-021, RNX-022, and RNX-023 for the treatment of chronic skin ulcers; RNX-041 for the treatment of inflammatory bowel diseases, such as chrons and pouchitis; and RNX-051 for the treatment of colorectal cancer and colon adenoma that are in Phase II clinical trials. The company was incorporated in 2002 and is headquartered in Horsholm, Denmark.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Horsholm, Denmark
- Employees
- 5
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.